Dongbo Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dongbo Yang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Marsha Rich Rosner
Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA
6 shared publications Andrea Valdespino
Ben May Department for Cancer Research, The University of Chicago, Chicago, USA
4 shared publications- Long Chi Nguyen
University of Chicago, Chicago, IL
4 shared publications Madeline Henn
Ben May Department for Cancer Research, The University of Chicago, Chicago, USA
4 shared publicationsChristopher Dann
Ben May Department for Cancer Research, The University of Chicago, Chicago, USA
3 shared publications- Christopher Dann
University of Chicago, Chicago, IL
3 shared publications
Latest Publications
- 30 August 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (2) , 247-255
Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors
Many oncogenic transcription factors (TFs) are considered to be undruggable because of their reliance on large protein–protein and protein–DNA interfaces. TFs such as hypoxia-inducible factors (HIFs) and X-box-binding protein 1 (XBP1) are induced by hypoxia and other stressors in solid tumors and bind to unfolded protein response element (UPRE) and hypoxia-induced response element (HRE) motifs to control oncogenic gene programs. Here, we report a strategy to create synthetic transcriptional repressors (STRs) that mimic the basic leucine zipper domain of XBP1 and recognize UPRE and HRE motifs. A lead molecule, STR22, binds UPRE and HRE DNA sequences with high fidelity and competes with both TFs in cells. Under hypoxia, STR22 globally suppresses HIF1α binding to HRE-containing promoters and enhancers, inhibits hypoxia-induced gene expression and blocks protumorigenic phenotypes in triple-negative breast cancer (TNBC) cells. In vivo, intratumoral and systemic STR22 treatment inhibited hypoxia-dependent gene expression, primary tumor growth and metastasis of TNBC tumors. These data validate a novel strategy to target the tumor hypoxia response through coordinated inhibition of TF–DNA binding.
- 30 August 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (2) , 247-255
Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors
Many oncogenic transcription factors (TFs) are considered to be undruggable because of their reliance on large protein–protein and protein–DNA interfaces. TFs such as hypoxia-inducible factors (HIFs) and X-box-binding protein 1 (XBP1) are induced by hypoxia and other stressors in solid tumors and bind to unfolded protein response element (UPRE) and hypoxia-induced response element (HRE) motifs to control oncogenic gene programs. Here, we report a strategy to create synthetic transcriptional repressors (STRs) that mimic the basic leucine zipper domain of XBP1 and recognize UPRE and HRE motifs. A lead molecule, STR22, binds UPRE and HRE DNA sequences with high fidelity and competes with both TFs in cells. Under hypoxia, STR22 globally suppresses HIF1α binding to HRE-containing promoters and enhancers, inhibits hypoxia-induced gene expression and blocks protumorigenic phenotypes in triple-negative breast cancer (TNBC) cells. In vivo, intratumoral and systemic STR22 treatment inhibited hypoxia-dependent gene expression, primary tumor growth and metastasis of TNBC tumors. These data validate a novel strategy to target the tumor hypoxia response through coordinated inhibition of TF–DNA binding.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (12_Supplem) , C070
Abstract C070: BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is more prevalent among African American and underserved female populations. Hypoxia has recently been identified as one of the main drivers of TNBC, particularly within the African American cohort. Therefore, it is important to identify and target key regulators of hypoxia. Here we show that the pro-metastatic transcription factor BACH1 is induced by hypoxia and regulates the hypoxia response in TNBC tumor cells. BACH1 protein is destabilized via an oxygen-dependent prolyl-hydroxylation pathway, akin to Hypoxia-inducible Factors (HIFs). BACH1 mutants (BACH1M) resistant to hydroxylation exhibit heightened transcriptional activity and metastatic potential both in vitro and in vivo. TGCA analysis reveals that TNBC exhibits elevated BACH1 mRNA and hypoxia signature, irrespective of racial ancestry. Nevertheless, racial disparities in BACH1 mRNA expression exist across all breast cancer subtypes (Basal, Her, LumA, LumB). Our findings suggest that BACH1 is an oxygen-sensitive mediator of hypoxia and a promising therapeutic target for mitigating hypoxia-induced pro-metastatic signaling and treatment resistance. These results also highlight the necessity of accounting for racial differences in BACH1 expression and function as a means of developing targeted therapy that takes into account racial disparities in TNBC. Citation Format: Long C. Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Leticia Stock, Madeline Henn, Galina Khramtsova, Wenchao Liu, Mitsuyo Matsumoto, Olufunmilayo Olopade, Kazuhiko Igarashi, Marsha Rosner. BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C070.
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (12_Supplem) , C070
Open AccessAbstract C070: BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is more prevalent among African American and underserved female populations. Hypoxia has recently been identified as one of the main drivers of TNBC, particularly within the African American cohort. Therefore, it is important to identify and target key regulators of hypoxia. Here we show that the pro-metastatic transcription factor BACH1 is induced by hypoxia and regulates the hypoxia response in TNBC tumor cells. BACH1 protein is destabilized via an oxygen-dependent prolyl-hydroxylation pathway, akin to Hypoxia-inducible Factors (HIFs). BACH1 mutants (BACH1M) resistant to hydroxylation exhibit heightened transcriptional activity and metastatic potential both in vitro and in vivo. TGCA analysis reveals that TNBC exhibits elevated BACH1 mRNA and hypoxia signature, irrespective of racial ancestry. Nevertheless, racial disparities in BACH1 mRNA expression exist across all breast cancer subtypes (Basal, Her, LumA, LumB). Our findings suggest that BACH1 is an oxygen-sensitive mediator of hypoxia and a promising therapeutic target for mitigating hypoxia-induced pro-metastatic signaling and treatment resistance. These results also highlight the necessity of accounting for racial differences in BACH1 expression and function as a means of developing targeted therapy that takes into account racial disparities in TNBC. Citation Format: Long C. Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Leticia Stock, Madeline Henn, Galina Khramtsova, Wenchao Liu, Mitsuyo Matsumoto, Olufunmilayo Olopade, Kazuhiko Igarashi, Marsha Rosner. BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C070.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4807
Abstract 4807: BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer
Hypoxia is an important hallmark of aggressive solid tumors. Here we show that the pro-metastatic BTB and CNC homology 1 (BACH1) transcription factor is prolyl-hydroxylated by the HIF Prolyl Hydroxylase 1 (PHD1) in an oxygen-dependent manner. Using mass spectrometry, we identified two major prolyl hydroxylation sites in BACH1 and demonstrate that prolyl hydroxylation increased protein turnover in normoxia. Notably, a clinically relevant BACH1 mutant (BACH1M) resistant to hydroxylation displays enhanced BACH1 DNA binding capacity. Triple-negative breast cancer (TNBC) cells expressing BACH1M showed higher invasion in vitro and increased metastasis in vivo. Loss of BACH1 reduced the cellular transcriptional hypoxic response. Under hypoxia, BACH1 increases chromatin accessibility and gene expression through chromatin remodeling involving direct BACH1 binding and indirect epigenetic regulation. These results indicate that hypoxia stabilizes and enhances the pro-metastatic transcriptional activity of BACH1 through loss of prolyl hydoxylation in TNBC. Our findings identify BACH1 as an oxygen sensitive effector of the hypoxia response and a clinically relevant target for attenuating hypoxia induced, pro-metastatic signaling and therapeutic resistance in cancers. Citation Format: Long Chi Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Joseph Wynne, Letícia Stock, Madeline Henn, Zeyu Qiao, Andrea Valdespino, Raven Watson, Wenchao Liu, Lydia Robinson-Mailman, Galina Khramtsova, Mitsuyo Matsumoto, Raymond Moellering, Olufunmilayo I. Olopade, Kazuhiko Igarashi, Marsha R. Rosner. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4807.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4807
Abstract 4807: BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer
Hypoxia is an important hallmark of aggressive solid tumors. Here we show that the pro-metastatic BTB and CNC homology 1 (BACH1) transcription factor is prolyl-hydroxylated by the HIF Prolyl Hydroxylase 1 (PHD1) in an oxygen-dependent manner. Using mass spectrometry, we identified two major prolyl hydroxylation sites in BACH1 and demonstrate that prolyl hydroxylation increased protein turnover in normoxia. Notably, a clinically relevant BACH1 mutant (BACH1M) resistant to hydroxylation displays enhanced BACH1 DNA binding capacity. Triple-negative breast cancer (TNBC) cells expressing BACH1M showed higher invasion in vitro and increased metastasis in vivo. Loss of BACH1 reduced the cellular transcriptional hypoxic response. Under hypoxia, BACH1 increases chromatin accessibility and gene expression through chromatin remodeling involving direct BACH1 binding and indirect epigenetic regulation. These results indicate that hypoxia stabilizes and enhances the pro-metastatic transcriptional activity of BACH1 through loss of prolyl hydoxylation in TNBC. Our findings identify BACH1 as an oxygen sensitive effector of the hypoxia response and a clinically relevant target for attenuating hypoxia induced, pro-metastatic signaling and therapeutic resistance in cancers. Citation Format: Long Chi Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Joseph Wynne, Letícia Stock, Madeline Henn, Zeyu Qiao, Andrea Valdespino, Raven Watson, Wenchao Liu, Lydia Robinson-Mailman, Galina Khramtsova, Mitsuyo Matsumoto, Raymond Moellering, Olufunmilayo I. Olopade, Kazuhiko Igarashi, Marsha R. Rosner. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4807.
- Open Access
Analysis of Gene Expression Heterogeneity Reveals Therapeutic Targets and Novel Regulators of Metastasis
Tumor cell heterogeneity has been implicated in metastatic progression of solid tumors such as triple-negative breast cancer (TNBC), leading to resistance and recurrence. We hypothesized that genes with low cell-to-cell transcriptional variability may be effective therapeutic targets, and that analysis of variability may facilitate identification of new metastatic regulators. Here we demonstrate, using single cell RNA sequencing, that the metastasis suppressor Raf Kinase Inhibitory Protein (RKIP) reduced overall transcriptional variability in TNBC xenograft tumors. Focusing on genes with reduced variability in response to RKIP, we identified targetable gene sets such as oxidative phosphorylation and showed that metformin could inhibit RKIP-expressing but not control tumor growth. We also found many regulators of cancer progression including a novel epigenetic metastasis suppressor, KMT5C. These studies demonstrate that a metastatic regulator can alter transcriptional variability in tumors and reveal the importance of genes involved in heterogeneity as potential therapeutic targets and regulators of metastatic progression in cancer.
Open AccessAnalysis of Gene Expression Heterogeneity Reveals Therapeutic Targets and Novel Regulators of Metastasis
Tumor cell heterogeneity has been implicated in metastatic progression of solid tumors such as triple-negative breast cancer (TNBC), leading to resistance and recurrence. We hypothesized that genes with low cell-to-cell transcriptional variability may be effective therapeutic targets, and that analysis of variability may facilitate identification of new metastatic regulators. Here we demonstrate, using single cell RNA sequencing, that the metastasis suppressor Raf Kinase Inhibitory Protein (RKIP) reduced overall transcriptional variability in TNBC xenograft tumors. Focusing on genes with reduced variability in response to RKIP, we identified targetable gene sets such as oxidative phosphorylation and showed that metformin could inhibit RKIP-expressing but not control tumor growth. We also found many regulators of cancer progression including a novel epigenetic metastasis suppressor, KMT5C. These studies demonstrate that a metastatic regulator can alter transcriptional variability in tumors and reveal the importance of genes involved in heterogeneity as potential therapeutic targets and regulators of metastatic progression in cancer.
- Top Cited PapersOpen Access
- 25 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (8) , eabi6110
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against current use of non-medical formulations as a preventative or treatment therapy.
- 25 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (8) , eabi6110
Top Cited PapersOpen AccessCannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against current use of non-medical formulations as a preventative or treatment therapy.
- Open Access
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Open AccessCannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.